Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Multiple Sclerosis: early-phase trial registry
120 of 317 indexed Multiple Sclerosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #24 of 28,707 conditions by registered trial count.
317 US clinical trials · 120 currently recruiting · #24 of 28,707 conditions by registered trial count
Multiple Sclerosis: 317 US clinical trials tracked, 120 recruiting.
Multiple Sclerosis is the subject of 317 registered US clinical trials on ClinicalTrials.gov, 120 of them currently open to new participants. 41 are in Phase 3-4 (later-stage) and 74 in Phase 1-2 (earlier-stage). The most active sponsor is Biogen, running 13 of these trials.
Enrollment posture brief
Registry condition multiple-sclerosis
OPEN 120 | RECR 38% | LATE 41 | EARLY 74 | RANK #24 | SPON 13
Volume-matched condition peers
Nearest open-share peer: Multiple Myeloma (38% recruiting · 441 trials)
Multiple Sclerosis lists 120 open slots (38% of 317 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Multiple Sclerosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Multiple Sclerosis recruits in line with its size-band peers.
120 of 317 indexed trials (37.9%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Multiple Sclerosis trials is spread across many organizations.
Biogen accounts for 13 of 317 trials (4.1%). 142 distinct sponsors appear on at least one study for this condition label.
-
Typical Multiple Sclerosis enrolment sits around 61 participants.
Median target enrolment is 61 among the 316 trials that report a genuine target (sentinel values excluded). 181 of those (57.3%) plan for fewer than 100 participants.
-
Multiple Sclerosis research is mostly interventional.
231 interventional and 86 observational studies make up this index (72.9% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
317 total, page 6 of 7
Emotion Regulation Skills Training for Individuals With MS and Their Support Partners
Johns Hopkins University
NCT03934489
Assistive Device Training in Multiple Sclerosis
Portland VA Medical Center
NCT02408718
Antibiotic Treatment Trial Directed Against Chlamydia Pneumonia in Multiple Sclerosis
National Center for Research Resources (NCRR)
NCT00043264
Consolidation & Interference in Multiple Sclerosis
Kessler Foundation
NCT02081508
MS Symptom Management Study
University of Washington
NCT02474940
Pilot Diet Study for Multiple Sclerosis
Icahn School of Medicine at Mount Sinai
NCT02986893
Improving Prospective Memory Via Telehealth
Trinity Health Of New England
NCT05129293
Exercise as a Strategy to Treat Cognitive Dysfunction in Persons With Multiple Sclerosis
University of California, Los Angeles
NCT01219647
31P-MRS Imaging to Assess the Effects of CNM-Au8 on Impaired Neuronal Redox State in Multiple Sclerosis.
Clene Nanomedicine
NCT03993171
Feasibility of Remote Exercise Training for Hispanics/Latinos With MS
University of Illinois at Chicago
NCT05998616
Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis
The Cleveland Clinic
NCT02065284
Waking Hypnosis in the Treatment of MS-related Fatigue
University of Washington
NCT04429789
Pilot Study of Transcranial Direct Current Stimulation (tDCS)
NYU Langone Health
NCT02746705
Evaluation of a Web-Based Fall Prevention Program on People With Multiple Sclerosis
Oregon Health and Science University
NCT02885233
E-Support Groups in Multiple Sclerosis
Columbia University
NCT03574961
Restoration of Walking in Multiple Sclerosis Using Treadmill Training.
US Department of Veterans Affairs
NCT00156676
EARLY IFNb-1a and Atorvastatin Combination Therapy of Isolated Clinical Syndrome Suggestive of Multiple Sclerosis
University of North Carolina, Chapel Hill
NCT00137176
Melatonin for Sleep in MS
University of California, San Francisco
NCT04035889
Natalizumab in Preventing Post-partum Relapses in Multiple Sclerosis
State University of New York at Buffalo
NCT03046251
Examining the Effects of Video-game Exercise on Mobility and Brain Plasticity in Individuals With Multiple Sclerosis
Ohio State University
NCT01780792
Anesthetic Topical Adhesive (Synera™) to Reduce Injection Pain With Subcutaneous Multiple Sclerosis Medications
Brown, Theodore R., M.D., MPH
NCT01834586
Impact Program for Multiple Sclerosis
University of Alabama at Birmingham
NCT05165238
Functional and Physiological Responses to Lokomat Therapy (Pilot Study)
US Department of Veterans Affairs
NCT00883142
12-week Safety Evaluation of Oral CS-0777 in Multiple Sclerosis Patients
Daiichi Sankyo
NCT00616733
Ocrelizumab Effects on the Metabolome in MS
Johns Hopkins University
NCT03873389
A TSEC for Symptom Management in Menopausal Women With Multiple Sclerosis
University of California, San Francisco
NCT02710214
Meningeal Inflammation on 7T MRI as a Tool for Measuring and Predicting Ocrelizumab Response in Multiple Sclerosis
University of Maryland, Baltimore
NCT03396822
Body Weight Supported Treadmill Training in Persons With Multiple Sclerosis
University of Illinois at Urbana-Champaign
NCT01992679
Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple Sclerosis
NYU Langone Health
NCT03658668
Management of Pain in Persons With Multiple Sclerosis
University of Washington
NCT00621374
Medical Marijuana and Its Effects on Motor Function in People With Multiple Sclerosis
Colorado State University
NCT02898974
Memantine for Spasticity in MS Patients
University of Rochester
NCT00638027
Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
University of Rochester
NCT01236534
Tysabri Effects on Cognition and Neurodegeneration in Multiple Sclerosis
University of Chicago
NCT01071512
A Wheelchair Propulsion Training Program
Washington University School of Medicine
NCT04009187
Safety of RG2077 in Patients With Multiple Sclerosis
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00076934
Experimental Evaluation of Wheelchair-Mounted Robotic Arms
University of South Florida
NCT01652352
Cognitive Motor Interference Rehabilitation in Persons With Multiple Sclerosis
University of Illinois at Urbana-Champaign
NCT02274935
My MS Toolkit: a Symptom Self-management Program for Multiple Sclerosis
University of Michigan
NCT03708276
The Role of Serum Leptin Levels in Multiple Sclerosis Disease Activity While on Interferon Beta 1a (Rebif) Treatment
University of South Florida
NCT01067573
Phase I Study of High-Dose Cyclophosphamide and Total Body Irradiation With T Lymphocyte-Depleted Autologous Peripheral Blood Stem Cell or Bone Marrow Rescue in Patients With Multiple Sclerosis
Northwestern Memorial Hospital
NCT00017628
A Pharmacokinetic (PK) Study of Natalizumab (Tysabri) at Steady State
Biogen
NCT00744679
Study to Evaluate the Feasibility of [18F]Florbetapir PET for Assessment in MS Patients
Institute for Neurodegenerative Disorders
NCT01767493
Comparing Risk and Severity of IRRs in Patients Premedicated With Cetirizine vs. Diphenhydramine Prior to Ocrelizumab
Providence Health & Services
NCT04175834
Histaminergic Basis of Central Fatigue in Multiple Sclerosis - A Novel Approach
University of Miami
NCT03266965
Effects of Targeted Lower Extremity Joint Training on Multiple Sclerosis (MS) Gait Abnormalities
Mount Sinai Rehabilitation Hospital
NCT00906737
Anti-Inflammatory Type II Monocyte Induction by Glatiramer Acetate (Copaxone) Treatment of Multiple Sclerosis
University of California, San Francisco
NCT00819195
Functional Intermuscular Reduction of Spasticity
University of Oklahoma
NCT04403594
Multimodal Exercise Training to Reduce Frailty in People With Multiple Sclerosis
University of Kansas Medical Center
NCT06042244
A Pilot Randomized Controlled Trial: CoINTEGRATE
University of Michigan
NCT05732285
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 41 |
| Phase 2 | 33 |
| Phase 3 | 24 |
| Phase 4 | 17 |
Top Sponsors
Named interventions
Most-linked intervention names on Multiple Sclerosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Multiple Sclerosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Multiple Sclerosis page
317 registered trials, 120 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 120 Multiple Sclerosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Biogen sponsors the most Multiple Sclerosis trials on record, review their full trial history before evaluating a specific study. See Biogen's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Multiple Sclerosis condition card totals 317 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.